Health and Healthcare

Wednesday's Top Biotech & Medical Stocks

by H.S. Ayoub
BioHealth Investor.com

Biotechnology

OSIRIS THERAPEUTICS [OSIR] +12.53%
EMERGENT BIOSOLUTION [EBS] +9.25%
ZIOPHARM ONCOLOGY IN [ZIOP] +8.91%
NANOGEN INC [NGEN] +8.20%
NEURO-HITECH INC [NHPI.OB] +6.60%

Diagnostic Substances

ADVANCE MAGNETIC [AMAG] +6.49%
REMOTEMDX INC [RMDX.OB] +6.25%
AMER BIO MEDICA [ABMC] +5.45%
AVALON PHARMACEUTIC [AVRX] +4.89%
RG GLBL LIFESTYLS [RGBL.OB] +4.20%

Drug Manufacturers

ATHEROGENICS INC [AGIX] +13.78%
RIGEL PHARMACEUTLS [RIGL] +10.94%
ISIS PHARM INC [ISIS] +6.91%
ADOLOR CORP [ADLR] +6.52%
PHARMAXIS LTD ADR [PXSL] +6.25%

Drug Related Products

AMEXDRUG CP [AXRX.OB] +7.14%
TIENS BIOTECH GR USA [TBV] +4.43%
AUXILIUM PHARMACEUT [AUXL] +4.37%
LABOPHARM INC. [DDSS] +2.95%
USANA HEALTH SCIEN [USNA] +2.80%

Generic Drugs

CATALYST PHARMACEUTI [CPRX] +4.23%
ISOLAGEN INC [ILE] +2.69%
HI-TECH PHARMACAL [HITK] +1.44%
CARACO PHARMA LABS [CPD] +1.09%
WATSON PHARMACEUTCLS [WPI] +1.07%

Medical Appliances & Equipment

SPECTRASCIENCE NEW [SCIE.OB] +13.04%
MEDICALCV INC [MCVI.OB] +10.67%
MICRUS ENDOVASCULAR [MEND] +8.44%
ENDOCARE INC [ENDO.OB] +6.80%
BSD MEDICAL CORP [BSM] +6.24%

Medical Instruments & Supplies

CARDIOTECH INTL [CTE] +9.30%
ENCISION INC [ECI] +8.03%
XTENT INC [XTNT] +5.47%
THORATEC CORP [THOR] +4.76%
LUXOTTICA GP SPA [LUX] +4.33%

Medical Laboratories & Research

SPHERIX INC [SPEX] +10.95%
PHARM PROD DEV [PPDI] +2.70%
ARRAY BIOPHARMA IN [ARRY] +2.66%
BIO-IMAGING TECH [BITI] +2.61%
OSI PHARMACEUTIC [OSIP] +2.19%

http://www.biohealthinvestor.com/

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.